bioRxivPharmacology & Toxicology
Mimicry of dopamine 1 receptor signaling with Cell-Penetrating Peptides
Abstract
In this study, through the use of protein mimicry, a peptide was developed to activate the dopamine 1 receptor signaling pathway in substitution of L-DOPA. The peptide proved to be capable of efficiently ubiquitously penetrating the cell without the need for transfection agents or chiral recognition by specific pathways. Furthermore, the peptide induced the cellular response normally achieved through the activation of the receptor in cells that had not been treated with the natural ligand. The peptide could work as a candidate substitute to L-DOPA, leading the way for a peptides-based treatment for Parkinsons disease.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Dopamine D1 receptor signalling in dyskinetic Parkinsonian rats revealed by fiber photometry using FRET-based biosensors
Jace Jones-Tabah, Hanan Mohammad, … Terence E. Hébert·Scientific ReportsPeer-reviewed·Sep 2, 2020
- D1, not D2, dopamine receptor activation dramatically improves MPTP-induced parkinsonism unresponsive to levodopa
Richard B. Mailman, Yang Yang, Xuemei Huang·European Journal of PharmacologyPeer-reviewed·Dec 3, 2020
- Dopamine D3 Receptor Ligand Suppresses the Expression of Levodopa-Induced Dyskinesia in Nonhuman Primate Model of Parkinson's Disease
Thomas T Oh, Elyas S. Daadi, … Marcel M. Daadi·Experimental NeurologyPeer-reviewed·Nov 8, 2021
- Brain-specific PP1/LRRK2 interaction-targeting peptides as a novel strategy for Parkinson's disease treatment
Séverine Loisel, Fanny Petit, … Angelita Rebollo·bioRxiv·Jul 29, 2026
- Covalent Modification and Regulation of the Nuclear Receptor Nurr1 by a Dopamine Metabolite
J. M. Bruning, Y. Wang, … P. M. England·bioRxiv·Nov 7, 2018
- Differential activation states of direct pathway striatal output neurons associated with the development of L-DOPA-induced dyskinesia.
David A. Figge, Henrique de Amaral Oliveira, … Karen L. Eskow Jaunarajs·bioRxiv·Nov 3, 2023